LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 1476 | 3177 | 3734 | 0.8508 | 0.7726 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 1476 | 3297 | 3413 | 0.9659 | 0.9435 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 1476 | 3293 | 3783 | 0.8704 | 0.8055 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 1476 | 3292 | 3734 | 0.8816 | 0.8203 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 1476 | 3564 | 3413 | 1.0442 | 1.0728 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 1476 | 3443 | 3783 | 0.9100 | 0.8658 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 1476 | 3275 | 3734 | 0.8771 | 0.8133 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 1476 | 3438 | 3413 | 1.0072 | 1.0120 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 1476 | 3743 | 3783 | 0.9893 | 0.9842 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 1476 | 3645 | 3734 | 0.9762 | 0.9643 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1476 | 3358 | 3413 | 0.9838 | 0.9732 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1476 | 3517 | 3783 | 0.9296 | 0.8952 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1476 | 3639 | 3734 | 0.9745 | 0.9618 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 1 | B07 | 72 | hr | 1476 | 2031 | 3413 | 0.5950 | 0.3017 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 2 | B07 | 72 | hr | 1476 | 1647 | 3783 | 0.4353 | 0.0837 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 3 | B07 | 72 | hr | 1476 | 1514 | 3734 | 0.4055 | 0.0188 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1476 | 4520 | 3788 | 1.1930 | 1.2773 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1476 | 4113 | 3731 | 1.1023 | 1.1511 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1476 | 3934 | 3796 | 1.0362 | 1.0529 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 1476 | 4167 | 3788 | 1.0999 | 1.1451 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 1476 | 4037 | 3731 | 1.0820 | 1.1213 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 1476 | 3751 | 3796 | 0.9880 | 0.9823 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 1476 | 3947 | 3788 | 1.0418 | 1.0612 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 2 | I10 | 72 | hr | 1476 | 3559 | 3731 | 0.9538 | 0.9306 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 3 | I10 | 72 | hr | 1476 | 3815 | 3796 | 1.0048 | 1.0071 |